Prognostic value of Oncogenetic mutations in pediatric T Acute Lymphoblastic Leukemia: a comparison of UKALL2003 and FRALLE2000T protocols

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial

Ajay Vora, Nick Goulden, Rachel Wade et al. · The Lancet Oncology · 2013 · 483 citations · Full text

Medicine, Hematology, Oncology +16

High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia

Alejandro Gutiérrez, Takaomi Sanda, Ruta Grebliunaite et al. · Blood · 2009 · 438 citations · Full text

Medicine, Molecular Biology, Oncology +14

Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial

Catriona Parker, Rachel Waters, Carly Leighton et al. · The Lancet · 2010 · 335 citations · Full text

Medicine, Oncology, Pediatrics +14

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial

Ajay Vora, Nick Goulden, Chris Mitchell et al. · The Lancet Oncology · 2014 · 305 citations · Full text

Medicine, Oncology, Pediatrics +13

Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia

Stephen Breit, Martin Stanulla, Thomas Flohr et al. · Blood · 2006 · 294 citations · Full text

Medicine, Genetics, Oncology +15